ESMO 2017 Highlights in Breast Cancer: Further Progress in ER+/HER2- Disease

Speaker: Aleix Prat

Aleix Prat points out the importance of the results presented during the ESMO 2017 Congress for the breast cancer community. 

Aleix Prat points out the importance of the results presented during the ESMO 2017 Congress for the breast cancer community.

Angelo Di Leo explains that the MONARCH 3 study was designed to determine whether we can improve the activity of endocrine therapy by combining it with CDK4-6 inhibitor therapy in ER+/HER2- advanced breast cancer patients. As expected, the combination improves the efficacy both clinically and statistically, with an observed 46% decrease in risk of progression.

Paul Cottu shows in the NeoPAL study that endocrine therapy plus CDK4/6 inhibition is not better than neoadjuvant chemotherapy in luminal stage II/III ER+/HER2- breast cancer.

The ExteNet trial focuses on early-stage HER2+ breast cancer patients. Miguel Martin explains that the idea was to add neratinib to the standard chemotherapy plus trastuzumab therapy. The 5-year results confirm the overall benefit with neratinib. Further studies are needed to confirm if standard therapy should be completed with one-year neratinib for high-risk HR+ patients.

The LORELEI study tested the addition of a PIK3CA alpha inhibitor on top of endocrine therapy in post-menopausal ER+/HER2- early breast cancer patients. Cristina Saura reports that tumour response is increased with the combination. A larger phase III trial will be needed to tell us if this should change clinical practice.



  • 236O_PR MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer
  • LBA9 - Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of luminal breast cancer. Results of the UNICANCER-NeoPAL study
  • ER+/HER2-negative early breast cancer (EBC)
  • 149O - Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5?year analysis of the phase III ExteNET trial
  • LBA10_PR - Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)

More resources from ESMO 2017 Congress